Immutopics, Inc. was acquired by Diagnostic Hybrids, Inc., a wholly owned subsidiary of Quidel Corporation, on March 18, 2016. Quidel is excited to have Immutopics join the Quidel family and portfolio of products and believes the combination of the Immutopics portfolio with Quidel's MicroVueTM products will enhance our ability to serve the bone health research community. Please see About Us for additional information.


FGF-23 (Intact) *2nd Generation Method*

For the Quantitative Determination of Human Intact FGF-23 Levels in Plasma or Cell Culture Media.

Description Item # (µL) Incubation Time Sensitivity Type
ELISA kit 60-6600 50 2 hr + 1 hr + 30 min 1.5 pg/mL 96 well microplate
(2nd Generation)